DM was identified as a strong independent predictor of stroke (HR = 3.09; 95% CI 1.15–8.29; p = 0.02); TVR (HR = 2.10; 95% CI 1.30–3.38, p = 0.002) and TVR (HR = 1.66; 95% CI 1.15–2.39, p = 0.006).

Conclusions: Among this large series of consecutives pts undergoing LM PCI, DM was not associated with an increase in death or ST, but was independently predictive of stroke, TVR and TLR at 6-year follow-up.

TCT-417
Left Ventricular Assist Improves 90 Day Outcomes With Unprotected Left Main Coronary Intervention: Analysis From The Protect II Trial
Alan W. Heldman1, Mauricio G. Cohen2, Simon Dixon3, Jeffrey W. Moses4, Igor F. Palacios5, Ashish Pershad6, William W. O’Neill2
1University of Miami, Miller School of Medicine, Miami, FL, 2University of Miami Miller School of Medicine, Miami, United States, 3Beaumont Hospital, Royal Oak, MI, 4NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, 5Massachusetts General Hospital, Boston, Massachusetts, 6Banner Good Samaritan Medical Center, Phoenix, AZ, 7Henry Ford Hospital, Detroit, Michigan

Background: Patients with severe left ventricular (LV) dysfunction undergoing intervention (PCI) upon the unprotected left main coronary (ULM) or the last remaining conduit (LRC) are susceptible to peri-procedural heart failure or hypotension which may limit the effectiveness of revascularization efforts.

Methods: The Protect II trial compared an LV assist device (Impella 2.5) to intra-aortic ballon counterpulsation (IABP) in patients undergoing high risk coronary intervention. We report 90 day outcomes from the subset of study subjects treated with ULM or LRC intervention.

Results: A total of 448 patients were treated in the Protect II trial and of these 102 underwent ULM (34 Impella, 35 IABP) or another LRC (15 impella, 18 IABP) PCI per protocol definition. Of the ULM/LRC cohort (N=102), 50% had class 3 or 4 heart failure, and the mean LVEF was 26%. Procedural differences between the two groups included a trend for more use of rotational atherectomy (RA), (22.4% vs 9.4%, p=0.071) with Impella; when RA was used, patients on Impella were treated with longer atherecromy runs (94.1 vs 36.5 sec, p=0.026). Duration of device support was much shorter (1.6 vs 10.8 hours, p=0.013) with Impella compared to IABP. Comparing 90 day composite major adverse cardiac and cerebrovascular events (MACCE) of death, large myocardial infarction (MI) with CK-MB >340, stroke or MI (9.4% vs 17.9%, p=0.03); procedure time (4.2%) and was not associated with adverse clinical events during index hospitalization.

Conclusions: In this subgroup analysis of a randomized trial, in patients with severe LV dysfunction undergoing PCI to the ULM or LRC, the use of Impella LV assist during intervention was associated with a lower risk of major adverse events at 90 days compared to the use of a IABP.

TCT-418
Confirmation of the Prognostic Capability of the SYNTAX Score-II Among 1,528 Patients Who Underwent Left Main PCI
Philippe Generoux1, Bo Xu1, Yueen Yang1, Liang Xu2, Shubin Qiao2, Yongjian Wu2, 1Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, 2Tufts Hospital, National Center for Cardiovascular Diseases, Beijing, China

Background: Recently, the SYNTAX score-2 (SXs-2) was developed in an attempt to individualize and help the decision-making process between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in the management of complex coronary artery disease (CAD). We sought to evaluate and confirm the prognostic capability of the SXs-2 among a group of 1,528 consecutive patients who already underwent left main (LM) PCI.

Methods: Data from all consecutive patients from a single center undergoing LM PCI were prospectively collected. Coronary angiograms and the resulting SYNTAX scores (SXs) and residual SXs were assessed by an independent angiographic core laboratory, and then the SXs-II (segmental coronary revascularization procedures). Impella use was associated with less MACCE compared to IABP use (16.7% vs 34.0%; p=0.047). The difference in MACCE was mainly driven by fewer strokes (0% vs 5.7%) and repeat procedures (0% vs 11.3%) with Impella.

Conclusions: In this subgroup analysis of a randomized trial, in patients with severe LV dysfunction undergoing PCI to the ULM or LRC, the use of Impella LV assist during intervention was associated with a lower risk of major adverse events at 90 days compared to the use of a IABP.

TCT-419
Side branch patency after implantation of the novel DESolve bioresorbable vascular scaffold system in the treatment of de novo coronary lesions
Rodrigo A. Souza1, Ricardo A. Costa2, Stefan Verhey3, Joachim Schofer4, Jose d Costa Jr1, Daniel Chamüé2, Andre Ahiziad, Yan John5, Vinayak Bhath6, Lynn Morrison1, Sara Toiyobi, Alexandre Albiez7
1Cardiovascular Research Center, Sao Paulo, Brazil, 2Instituto Dante Pazzanese, Sao Paulo, Sao Paulo, 3Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium, 4Antwerp, Belgium, 5Medicare center Prof Mathy, Prof Schofer, Hamburg University Cardiovascular Center, Hamburg, Germany, 6Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil, 7Dante Pazzanese, Sao Paulo, Brazil, 8Elixir Medical Corporation, Sunnyvale, CA, 9Elixir medical corporation, Sunnyvale, CA, 10Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

Background: Background: The DESolve® novolimus-eluting bioresorbable vascular scaffold system (Elixir Medical Co., Sunnyvale, CA) is a novel bioresorbable vascular scaffold device that combines a PLLA-based scaffold (strut thickness 150 μm) coated with a potent antiproliferative sirolimus metabolite – Novolimus (5 μm per mm of scaffold length). Our aim was to investigate the occurrence of side branch (SB) compromise after implantation of the DESolve device in single de novo bifurcation lesions.

Methods: Methods: 126 patients/lesions were prospectively enrolled in the multicenter (13 sites), non-randomized, single-arm DESolve Ns trial. Lesion criteria were < 14 mm in length located in a native coronary vessel measuring 2.75-3.5 mm in diameter, SB compromise, de novo bifurcation vessel occlusion (TIMI flow 0/1 at post procedure, was evaluated within the treated segment covered by the study device at an independent angiographic core laboratory. All SBs >1.0 mm in diameter (by visual estimation) were considered for analysis.

Results: Results: Overall, there were 71 SBs >1.0 mm found in 123 coronary segments treated by 126 scaffolds (3 lesions did not receive the study device; 3 lesions received 2 study devices). The majority of SBs (96%) had pre-procedure TIMI 3 flow. During the procedure, neither guide wire protection nor intervention was performed in any SB. At post-procedure, SB occlusion was detected in only 3 cases, representing a 4.2% SB compromise rate. Importantly, there were no adverse clinical events during hospitalization associated with SB occlusion.

Conclusions: Conclusions: In the prospective, non-randomized, single-arm, multicenter DESolve Ns trial, SB compromise - as determined by vessel occlusion after implantation of the novel DESolve bioresorbable vascular scaffold, was relatively low (4.2%) and was not associated with adverse clinical events during index hospitalization.

TCT-420
First- versus Second-generation Drug-Eluting Stents for the Treatment of Coronary Bifurcations
Chari C. Costopoulos1, Aseem Latib2, Toru Nagamama3, Sandeep Batavachal4, Mauro Carlino5, Alada Chiefo6, Santo Ferrarello7, Filippo Figini7, Romeo Panerai4, Kawaguchi8, Matteo Montorfano6, Charbel Naim2, Alessandro Sticchi5, Antonio Colombo9
1San Raffaele Scientific Institute, Milan, Italy, 2Ospedale San Raffaele, Milan, Italy, 3San Raffaele Scientific Institute, Milan, Italy, 4Imperial College, London, London, 5NIA, Milan, Italy, 6San Raffaele Scientific Institute, Milan, Italy, 7San Raffaele scientific institute, Milano, Milano, 8EMO GVM Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy

Background: Background: Randomized controlled trials have demonstrated that of second-generation drug-eluting stents (DES) for the treatment of obstructive coronary artery disease is associated with comparable, if not improved, clinical outcomes as compared to that of their first-generation counterparts. The aim of this study was to compare the long-term clinical outcomes associated with first- versus second-generation DES for the treatment of coronary bifurcation lesions.

Methods: This was a retrospective study of consecutive de novo bifurcation lesions, excluding those at the left main, treated with either second-generation DES (everolimus-eluting or zotarolimus-eluting stents) between October 2006-October 2011 (199 bifurcation lesions in 192 patients) or first-generation DES (sirolimus-eluting or paclitaxel-eluting stents) between April 2002-December 2005 (289 bifurcation lesions in 273 patients).

Results: Second-generation DES use in this setting was associated with less major adverse cardiac events (MACE) (23.1% vs 14.4%, p = 0.02) as well as lower target vessel revascularization (TVR) (15.5% vs 8.3%, p = 0.01) at 2-year follow-up. Target lesion revascularization, both per patient (12.6% vs 7.4%, p = 0.02) and per bifurcation (11.8% vs 7.0%, p = 0.03), was also improved with second-generation DES over the same follow-up period. Propensity-score adjusted analysis suggested that first-generation DES was an independent predictor of both MACE (HR, 0.53; 95% CI, 0.33-0.85; p = 0.01) and TVR (HR, 0.44; 95% CI, 0.24-0.83; p = 0.01).

Conclusions: Our results suggest that the use of second-generation DES for the treatment of bifurcation lesions is associated with better clinical outcomes as compared to first-generation DES, largely due to a lower need for repeat revascularization.